Piramal Pharma share price
NSE: PPLPHARMABSE: 543635Pharmaceuticals & BiotechnologySmall Cap
Piramal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2022
Last close ₹232.80up ₹34.08 (17.15%)BSE ₹232.80
Share price at the NSE close on 28 Oct 2026. Previous close ₹198.72.
28 Oct: open ₹214.10, high ₹235.64, low ₹209.04
52-week range of traded prices to 28 Oct 2026
₹132.30Low, 23 Mar 2026₹235.64High, 28 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹30,994 Cr331st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.81
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −2.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹217 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 0.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.69
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,80,72,22815.7% delivered
About Piramal Pharma
Piramal Pharma Limited is a Mumbai-based pharmaceutical, health and wellness company.12 It works through Piramal Pharma Solutions, which develops and manufactures drugs for other companies (a contract development and manufacturing organisation, or CDMO); Piramal Critical Care, which sells complex generic medicines to hospitals; and Piramal Consumer Healthcare, which sells over-the-counter consumer and wellness products.3 Its customers include pharmaceutical companies, hospitals, distributors, pharmacy chains, government institutions and retail consumers.4
It has 17 development and manufacturing facilities across North America, the UK and India, and a distribution network in over 100 countries.35 Regulated markets (countries with strict drug regulators) supplied 66% of its revenue in the year to Mar 2026.5 Its 6 consumer power brands are Little's, Lacto Calamine, i-range, CIR, Tetmosol and Polycrol.6 It also has a joint venture with AbbVie, AbbVie Therapeutics India, which sells eye-care brands including Pred Forte, Lumigan, Combigan, Refresh Tears and Alphagan, and to which its CDMO business supplies ophthalmology products.7
It was incorporated in 2020.8 It is part of the Piramal Group.9 The pharma business of Piramal Enterprises Limited was demerged into the company under a composite scheme of arrangement, under which Piramal Enterprises' shareholders were allotted its shares.1011 Its promoters include Ajay G. Piramal, Swati A. Piramal, Nandini Piramal and The Sri Krishna Trust; the trust and the shareholder CA Alchemy Investments each held more than 5% of the shares at the end of March 2026.1112
Piramal Pharma key points
Results
- In the quarter to Sep 2026, consolidated revenue from operations was ₹2,617 crore against ₹2,044 crore a year earlier, EBITDA (earnings before interest, tax, depreciation and amortisation) ₹385 crore against ₹224 crore, and net profit ₹5 crore against a ₹99 crore loss.13
- In the half year to Sep 2026, consolidated revenue from operations was ₹4,887 crore against ₹3,977 crore, EBITDA ₹669 crore against ₹389 crore, and the net loss after one-off items ₹64 crore against ₹181 crore.14
- In the year to Mar 2026, consolidated revenue from operations fell 3.08% to ₹8,869.08 crore from ₹9,151.18 crore, and EBITDA was ₹1,135 crore.1516
- The consolidated net loss for the year to Mar 2026 was ₹325.94 crore, against a profit of ₹91.13 crore a year earlier, after one-off items of ₹196.14 crore.17
Market position
Business segments
- Revenue by business, ₹ crore1420Group revenue from operations includes foreign exchange gains and losses and is not the sum of these rows.
Item half year to Sep 2026 half year to Sep 2025 Contract development and manufacturing 2,611 2,041 Complex hospital generics 1,592 1,281 Consumer healthcare 706 621 - In the half year to Sep 2026, Piramal Pharma Solutions' commercial manufacturing revenue from on-patent drugs (still under patent) grew 39%, its antibody-drug conjugate (ADC, a cancer drug linking a toxin to an antibody) revenue 51%, and it added 22 new customers.21
- In the half year to Sep 2026, Piramal Consumer Healthcare's Power Brands grew 21% and made up 53% of its sales, while its e-commerce sales grew 32% and made up 28%.2223
CDMO pipeline and customers
- Piramal Pharma Solutions had 157 molecules in development in March 2026; Phase III molecules (the last trial stage) rose to 28 by September 2026 from 25.2425
- Piramal Pharma Solutions commercially manufactures 16 on-patent molecules, which generated $96 million of revenue in the year to Mar 2026, lower than a year earlier because of inventory destocking in one product, the company says.26
- On its earnings call of 30 Jul 2026, the company said it had announced an ADC collaboration with Ajinomoto Bio-Pharma Services during the quarter to Jun 2026, and a manufacturing and supply agreement with Botanix for Sofdra.27
Plants and capacity
- Piramal Pharma Solutions' specialised sites make antibody-drug conjugates at Grangemouth (UK), high-potency ingredients at Riverview and Aurora (North America) and sterile injectables at Lexington (US).28
- Piramal Critical Care makes inhalation anaesthesia key starting materials at Dahej (India) and drug ingredients and finished products at Digwal (India) and Bethlehem (US).29
- Piramal Pharma Solutions' $90 million expansion programme covers sterile injectables at Lexington and ADC payload-linkers (the toxin-and-linker part) at Riverview; Riverview is complete, Lexington on track for completion by end-2027.3031
Quality and regulatory record
- In the half year to Sep 2026 the company cleared 12 regulatory inspections and 110 customer audits; no US FDA inspection has been classified Official Action Indicated (the most serious outcome).32
What the company expects
- In its presentation of 27 Oct 2026, the company said it now expects revenue growth of 19% to 20% in the year to Mar 2027.33
- On its earnings call of 30 Jul 2026, the company said it targets an EBITDA margin of 25% by the year to Mar 2030.34
- On its earnings call of 30 Jul 2026, the company said it had guided annual capital spending of $120 million to $135 million, of which it had spent about $21 million so far.35
- In its presentation of 27 Oct 2026, the company said its Bayer distribution agreement, worth ₹475 crore of revenue in the year to Mar 2026, expires in December 2026, with an expected impact under 2% on revenue in the year to Mar 2027.36
Recent events
- On 28 Sep 2026, the company received a GST order confirming a demand of ₹4,06,03,220 of input tax credit (tax paid on purchases, set against tax owed), plus interest and an equal penalty; it intends to appeal and expects no material impact.37
- A US FDA inspection of the Morpeth, UK plant ending 11 Sep 2026 produced a Form 483 (a list of findings) with 7 observations; the company said it was preparing its response.38
- In its exchange filing of 18 Aug 2026, the company said it had raised its stake in Yapan Bio, a vaccines and biologics CDMO, from 33.33% to 74.00% for about ₹76 crore.39
- On 1 Apr 2026, a subsidiary completed buying the Kenalog brands from Bristol-Myers Squibb for $35 million upfront plus up to $65 million tied to milestones.40
Last updated
All 40 sources, each with its page
- 1. Annual report, 3 Jul 2026, page 4
- 2. Annual report, 3 Jul 2026, page 95
- 3. Investor presentation, 27 Oct 2026, page 5
- 4. Annual report, 3 Jul 2026, page 65
- 5. Annual report, 3 Jul 2026, page 6
- 6. Annual report, 3 Jul 2026, page 9
- 7. Investor presentation, 27 Oct 2026, page 19
- 8. Annual report, 3 Jul 2026, page 1
- 9. Annual report, 3 Jul 2026, page 5
- 10. Annual report, 3 Jul 2026, page 153
- 11. Annual report, 3 Jul 2026, page 105
- 12. Annual report, 3 Jul 2026, page 146
- 13. Investor presentation, 27 Oct 2026, page 21
- 14. Investor presentation, 27 Oct 2026, page 21
- 15. Annual report, 3 Jul 2026, page 37
- 16. Annual report, 3 Jul 2026, page 13
- 17. Annual report, 3 Jul 2026, page 37
- 18. Investor presentation, 27 Oct 2026, page 16
- 19. Annual report, 3 Jul 2026, page 32
- 20. Investor presentation, 27 Oct 2026, page 21
- 21. Investor presentation, 27 Oct 2026, page 12
- 22. Investor presentation, 27 Oct 2026, page 17
- 23. Investor presentation, 27 Oct 2026, page 3
- 24. Annual report, 3 Jul 2026, page 15
- 25. Investor presentation, 27 Oct 2026, page 12
- 26. Annual report, 3 Jul 2026, page 30
- 27. Earnings call, 30 Jul 2026, page 3
- 28. Annual report, 3 Jul 2026, page 29
- 29. Annual report, 3 Jul 2026, page 33
- 30. Annual report, 3 Jul 2026, page 30
- 31. Earnings call, 30 Jul 2026, page 3
- 32. Investor presentation, 27 Oct 2026, page 15
- 33. Investor presentation, 27 Oct 2026, page 2
- 34. Earnings call, 30 Jul 2026, page 16
- 35. Earnings call, 30 Jul 2026, page 12
- 36. Investor presentation, 27 Oct 2026, page 18
- 37. Exchange filing, 29 Sep 2026, page 1
- 38. Exchange filing, 14 Sep 2026, page 1
- 39. Exchange filing, 18 Aug 2026, page 1
- 40. Annual report, 3 Jul 2026, page 54
Results
Consolidated; ₹ crore.Piramal Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,617 Crup 15.29%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹5.03 CrQuarter to Jun 2026: −₹69 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 0.2%
Revenue by quarter
Peak revenue ₹2,754 Cr, quarter to Mar 2025; lowest ₹1,934 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Sep 2026, ₹5.03 CrA loss in 5 of the 8 quarters shown
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 | 2,617 |
| Net profit | 4 | 154 | −82 | −99 | −136 | −9 | −69 | 5 |
| Net margin | 0.2% | 5.6% | −4.2% | −4.9% | −6.4% | −0.3% | −3.1% | 0.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹8,869 Crdown 3.08%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹326 CrYear to Mar 2025: ₹91 Cr
- Net margin
- −3.7%
Revenue by year
Peak revenue ₹9,151 Cr, year to Mar 2025; lowest ₹7,082 Cr, year to Mar 2023
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹326 CrA loss in 2 of the 4 years shown
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 7,082 | 8,171 | 9,151 | 8,869 |
| Net profit | −186 | 18 | 91 | −326 |
| Net margin | −2.6% | 0.2% | 1.0% | −3.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months.Piramal Pharma PE ratio and valuation
Price to book
At or below today's level on 91% of 903 trading days since Nov 2022.
LowestHighest
Its median2.81Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 49% of 970 trading days since Nov 2022.
LowestHighest
Its median0.04%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −39.2% | – | – | 0.0% |
| 3 years | +25.9% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Mutual fund holdings
103 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 55 of the 64 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 103 funds holding Piramal Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 41
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 32
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 6
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 7,18,36,476 | 1.37% | ₹1,483.6 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 99,37,272 | 2.24% | ₹205.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 98,96,924 | 0.57% | ₹204.4 Cr |
 Franklin India Opportunities FundFranklin Templeton Mutual Fund | 61,54,389 | 1.33% | ₹127.1 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 60,21,499 | 1.46% | ₹124.4 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 56,30,453 | 0.83% | ₹116.3 Cr |
| Franklin India Small Cap FundFranklin Templeton Mutual Fund | 51,09,343 | 0.74% | ₹105.5 Cr |
| Nippon India Small Cap FundNippon India Mutual Fund | 49,90,259 | 0.13% | ₹103.1 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 45,65,035 | 0.50% | ₹94.3 Cr |
| Canara Robeco Aggressive Hybrid FundCanara Robeco Mutual Fund | 31,50,000 | 0.60% | ₹65.1 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Piramal Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Piramal Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Piramal Pharma in market cap.Healthcare companies
Piramal Pharma is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 30,374 | 69.17 | 16.35 | +45.2% | +96.1% | 26.9% | 30.2% | 0.07% |
 Rubicon ResearchRUBICON | 25,889 | 89.83 | 20.09 | – | – | 22.4% | 25.8% | 0.10% |
 Neuland LaboratoriesNEULANDLAB | 25,621 | 51.47 | 13.67 | +78.3% | +182.6% | 29.3% | 32.1% | 0.17% |
 Granules IndiaGRANULES | 22,926 | 34.61 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Piramal Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.14 a share, year to Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 16 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.14 |
| 12 Jul 2024 | Final | ₹0.11 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Piramal Pharma announcements
Oct 2026
27 Oct · Results
16 Oct · Analysts
16 Oct · Board meeting
Piramal Pharma share price by year
Each calendar year to 2025.Piramal Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 172.21 | −35.3% | 258.25 | 166.52 |
| 2024 | 266.25 | +91.8% | 293.55 | 115.50 |
| 2023 | 138.85 | +21.1% | 140.50 | 63.95 |
| 2022 | 114.65 | – | 190.00 | 114.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2022 is from its first session, 19 Oct 2022.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 196.08 | 203.37 | 194.61 | 198.72 | 200.12 | 28,73,965 | 44.3% |
| 26 Oct 2026 | 190.00 | 195.75 | 188.52 | 195.17 | 193.59 | 14,71,129 | 40.4% |
| 23 Oct 2026 | 194.00 | 194.91 | 185.02 | 191.07 | 189.86 | 24,65,513 | 42.5% |
| 22 Oct 2026 | 190.51 | 196.35 | 188.22 | 194.99 | 193.35 | 28,35,616 | 31.8% |
| 21 Oct 2026 | 194.95 | 199.50 | 189.60 | 191.19 | 193.97 | 31,66,061 | 41.1% |
| 19 Oct 2026 | 197.00 | 201.73 | 193.81 | 194.44 | 197.40 | 13,18,209 | 37.9% |
| 16 Oct 2026 | 194.95 | 198.75 | 193.60 | 197.73 | 197.08 | 20,49,052 | 44.4% |
| 15 Oct 2026 | 193.50 | 196.39 | 192.62 | 194.43 | 194.29 | 29,95,160 | 74.9% |
| 14 Oct 2026 | 195.35 | 196.70 | 192.76 | 193.94 | 194.43 | 16,89,308 | 54.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 2 Aug 2023 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- PPLPHARMA
- BSE code
- 543635
- ISIN
- INE0DK501011
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.piramalpharma.com
- CIN
- L24297MH2020PLC338592
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2020
- Registered office
- Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai 400070, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap